<DOC>
	<DOCNO>NCT01509989</DOCNO>
	<brief_summary>The treatment systemic lupus erythematosus ( SLE ) may change future due availability new biological treatment , especially monoclonal antibody patient active disease . However , one main cause treatment failure SLE lack treatment adherence since `` drug n't work patient n't take . '' Hydroxychloroquine ( HCQ-Plaquenil ) long terminal elimination half- life , investigator demonstrate patient take HCQ long time undetectable very-low blood HCQ concentration ( &lt; 200 ng/ml ) . The rate severe non-adherence 7 % cohort 203 patient even high patient active disease : 8 35 ( 23 % ) patient SLEDAI ≥6 6 20 ( 30 % ) patient SLEDAI ≥12 . Investigators evaluate importance non-adherence treatment large population SLE patient active disease . This do blood HCQ monitoring translational multicentric prospective study .</brief_summary>
	<brief_title>International Prospective Study Adherence Treatment Patients With Active Systemic Lupus Erythematosus</brief_title>
	<detailed_description>This international multicentric prospective study observational study include consecutive SLE patient treat HCQ SLE flare ( define SELENA-SLEDAI flare composite ) . The study require sample 1 vial whole blood dosage HCQ ( would centralize perform PITIE-SALPETRIERE Hospital completion study ) . The patient physician also adherence self-questionnaires complete , physicians complete patient data sheet . The end point adherence treatment whole group , subgroup , adherence accord severity SLE , relationship patient 's questionnaire , physician evaluation adherence blood HCQ dosage . If investigator confirm previous data , study might demonstrate significant proportion patient candidate treatment escalation fact nonadherent treatment . It might demonstrate interest HCQ concentration monitoring , `` real life '' therapeutic study SLE may avoid unnecessary , expensive even hazardous regimen escalation .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Inclusion criterion : History meet 4 American College Rheumatology ( ACR ) criteria systemic lupus erythematosus include positive test antinuclear antibody , SLE flare define SELENASLEDAI flare composite Treatment HCQ least 2 month daily dosage &gt; equal 200 mg/day . Exclusion criterion : Patients able take medication ( notably patient repeat vomit patient allow take oral medication )</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Adherence</keyword>
	<keyword>Compliance</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Hydroxychloroquine</keyword>
	<keyword>Blood monitoring</keyword>
	<keyword>Flares</keyword>
</DOC>